Look out, Neu­las­ta: A 5th biosim­i­lar is com­ing

As Neu­las­ta sales slip, Am­gen has yet an­oth­er biosim­i­lar to look out for: Am­neal Phar­ma­ceu­ti­cals and Kashiv Bio­sciences’ Fly­ne­tra.

Fly­ne­tra be­came the fifth ap­proved biosim­i­lar to Neu­las­ta on Fri­day, snag­ging a win in neu­trope­nia, a con­di­tion com­mon among chemother­a­py pa­tients where neu­trophils, a type of white blood cell that fights in­fec­tion, are too low.

As of last sum­mer, the list price of Neu­las­ta was more than $6,400 per dose. It’s de­signed to be tak­en in a sin­gle dose per chemother­a­py cy­cle. Am­neal de­clined to re­veal how much it in­tends to charge for Fly­ne­tra in an email to End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER